FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226022832> ?p ?o ?g. }

• W4226022832 endingPage "987" @default.
• W4226022832 startingPage "973" @default.
• W4226022832 abstract "Most of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Behçet's syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effects and disease flares after COVID-19 vaccination with either Pfizer/BioNTech or Sinovac/CoronaVac in 256 patients with BS, 247 with FMF, and 601 with RD. Telephone interviews were conducted using a questionnaire survey in a cross-sectional design in patients with BS, FMF, and RD followed by a single university hospital. Study participants were vaccinated either with CoronaVac (BS:109, FMF: 90, and RD: 343,) or BioNTech (BS: 147, FMF: 157 and RD: 258). The majority have received double dose (BS: 94.9%, FMF 92.3% and RD: 86.2%). BioNTech ensured a significantly better efficacy than CoronaVac against COVID-19 in all patient groups (BS: 1.4% vs 10.1%; FMF: 3.2% vs 12.2%, RD:2.7% vs 6.4%). Those with at least one adverse event (AE) were significantly more frequent among those vaccinated with BioNTech than those with CoronaVac (BS: 86.4% vs 45%; FMF: 83.4% vs 53.3%; and RD: 83.3% vs 45.5%). The majority of AEs were mild to moderate and transient and this was true for either vaccine. There were also AEs that required medical attention in all study groups following CoronaVac (BS: 5.5%, FMF: 3.3%, and RD:2.9%) or BioNTech (BS: 5.4%, FMF: 1.9%, and RD: 4.7%). The main causes for medical assistance were disease flare and cardiovascular events. Patients with BS (16.0%) and FMF (17.4%) were found to flare significantly more frequently when compared to those with RD (6.0%) (p < 0.001). This was true for either vaccine. BS patients reported mainly skin-mucosa lesions; there were however, 11 (4.3%) who developed major organ attack such as uveitis, thrombosis or stroke. Flare in FMF patients were associated mainly with acute serositis with or without fever. Arthralgia/arthritis or inflammatory back pain were observed mainly in the RD group. Our study demonstrates that BS and FMF patients vaccinated with either CoronaVac or BioNTech demonstrated similar AE profile and frequency compared to RD patients. AEs that required physician consultation or hospitalization occurred in all study groups after either CoronaVac or BioNTech. Increased frequency of flares in BS and FMF compared to that seen in RD might reflect defects in innate immunity and deserves further investigation. Caution should be required when monitoring these patients after vaccination." @default.
• W4226022832 created "2022-05-05" @default.
• W4226022832 creator A5016020985 @default.
• W4226022832 creator A5026992017 @default.
• W4226022832 creator A5028532551 @default.
• W4226022832 creator A5029844978 @default.
• W4226022832 creator A5032846134 @default.
• W4226022832 creator A5039434152 @default.
• W4226022832 creator A5047872744 @default.
• W4226022832 creator A5057143554 @default.
• W4226022832 creator A5057516412 @default.
• W4226022832 creator A5061759237 @default.
• W4226022832 creator A5062409928 @default.
• W4226022832 creator A5063297960 @default.
• W4226022832 creator A5084990881 @default.
• W4226022832 creator A5085758606 @default.
• W4226022832 date "2022-04-04" @default.
• W4226022832 modified "2023-10-01" @default.
• W4226022832 title "Safety of SARS-CoV-2 vaccination in patients with Behcet’s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine" @default.
• W4226022832 cites W133131803 @default.
• W4226022832 cites W2122426810 @default.
• W4226022832 cites W2140276493 @default.
• W4226022832 cites W2146401589 @default.
• W4226022832 cites W2893117281 @default.
• W4226022832 cites W2955958274 @default.
• W4226022832 cites W3017185871 @default.
• W4226022832 cites W3036177844 @default.
• W4226022832 cites W3080102688 @default.
• W4226022832 cites W3108894477 @default.
• W4226022832 cites W3111255098 @default.
• W4226022832 cites W3134987890 @default.
• W4226022832 cites W3139524064 @default.
• W4226022832 cites W3147649730 @default.
• W4226022832 cites W3157637563 @default.
• W4226022832 cites W3158373340 @default.
• W4226022832 cites W3164069651 @default.
• W4226022832 cites W3169946064 @default.
• W4226022832 cites W3172019122 @default.
• W4226022832 cites W3173389157 @default.
• W4226022832 cites W3175995708 @default.
• W4226022832 cites W3178010802 @default.
• W4226022832 cites W3179399516 @default.
• W4226022832 cites W3179482482 @default.
• W4226022832 cites W3184492194 @default.
• W4226022832 cites W3185635616 @default.
• W4226022832 cites W3186114398 @default.
• W4226022832 cites W3189960128 @default.
• W4226022832 cites W3191062648 @default.
• W4226022832 cites W3192153993 @default.
• W4226022832 cites W3194517423 @default.
• W4226022832 cites W3195586393 @default.
• W4226022832 cites W3196528228 @default.
• W4226022832 cites W3197830587 @default.
• W4226022832 cites W3200749592 @default.
• W4226022832 cites W3201776787 @default.
• W4226022832 cites W3203540845 @default.
• W4226022832 cites W3204020232 @default.
• W4226022832 cites W3205292490 @default.
• W4226022832 cites W3205396847 @default.
• W4226022832 cites W3205823848 @default.
• W4226022832 cites W3211750341 @default.
• W4226022832 cites W3213516711 @default.
• W4226022832 cites W3214368855 @default.
• W4226022832 cites W3215659530 @default.
• W4226022832 cites W3216623344 @default.
• W4226022832 cites W4200329673 @default.
• W4226022832 cites W4200608310 @default.
• W4226022832 cites W4205362144 @default.
• W4226022832 cites W4205371641 @default.
• W4226022832 cites W4205483821 @default.
• W4226022832 cites W4207076468 @default.
• W4226022832 cites W4300492363 @default.
• W4226022832 cites W4300527789 @default.
• W4226022832 doi "https://doi.org/10.1007/s00296-022-05119-y" @default.
• W4226022832 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35376962" @default.
• W4226022832 hasPublicationYear "2022" @default.
• W4226022832 type Work @default.
• W4226022832 citedByCount "12" @default.
• W4226022832 countsByYear W42260228322022 @default.
• W4226022832 countsByYear W42260228322023 @default.
• W4226022832 crossrefType "journal-article" @default.
• W4226022832 hasAuthorship W4226022832A5016020985 @default.
• W4226022832 hasAuthorship W4226022832A5026992017 @default.
• W4226022832 hasAuthorship W4226022832A5028532551 @default.
• W4226022832 hasAuthorship W4226022832A5029844978 @default.
• W4226022832 hasAuthorship W4226022832A5032846134 @default.
• W4226022832 hasAuthorship W4226022832A5039434152 @default.
• W4226022832 hasAuthorship W4226022832A5047872744 @default.
• W4226022832 hasAuthorship W4226022832A5057143554 @default.
• W4226022832 hasAuthorship W4226022832A5057516412 @default.
• W4226022832 hasAuthorship W4226022832A5061759237 @default.
• W4226022832 hasAuthorship W4226022832A5062409928 @default.
• W4226022832 hasAuthorship W4226022832A5063297960 @default.
• W4226022832 hasAuthorship W4226022832A5084990881 @default.
• W4226022832 hasAuthorship W4226022832A5085758606 @default.
• W4226022832 hasBestOaLocation W42260228321 @default.
• W4226022832 hasConcept C126322002 @default.
• W4226022832 hasConcept C141071460 @default.

• next